Nestle (NESN) is banking on the increasingly growing skincare industry by purchasing the rights to several skincare treatments from Valeant Pharmaceuticals International (VTX).

The $1.4 billion purchase will nab Nestle commercial rights to sell facial treatments Restylane, Perlane and Emervel in the U.S. and Canada, and global rights for Sculptra.

“With this deal we have acquired key strategic assets to extend Nestle’s activities in the field of specialized, medical skin treatments, providing consumers with life-enhancing scientific products,” Nestle Chairman Peter Brabeck-Letmathe said in a statement.

The move is not unexpected, as in February the Swiss company that is the world’s biggest food group took the reigns of the Galderma dermatology venture with L’Oreal.

Via Reuters:

Wednesday’s move gives Nestle the North American rights to some products taken on in that deal, boosting its control of the brands and avoiding the situation with KitKat, to which rival Hershey owns the rights in the United States.

Citing data from GlobalData Facial Aesthetics, Vontobel analysts said the U.S. market for Botox and other wrinkle fillers, is set to grow from $2.5 billion in 2013 to $4.7 billion in 2018 – compound annual growth of 13.5 percent.

“These figures speak for themselves and explain how strategic the deal is for Nestle/Galderma,” the analysts stated in a research note. “Nestle did not want to be in a similar situation as for Hershey (with KitKat).”

NESN shares were up 0.4% in morning trading.